Vyant Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2021

	2021
Valuation assumptions
Expected dividend yield		0.0	%
Expected volatility		119.0% – 123.0	%
Expected term (years) – simplified method		5.5 – 6.1
Risk-free interest rate		0.98% – 1.12	%

Stock option activity during the six-month periods ended June, 2021 and 2020 is as follows:

Schedule of Share Option Activity

	Number of Options			Weighted average exercise price		Weighted average remaining contractual term
Balance as of January 1, 2020		509,173		$	1.30		7.4
Granted		449,926			2.01
Number of Options, Additional options to StemoniX option holders
Weighted average exercise price, Additional options to StemoniX option holders
Number of Options, assumed in Merger
Weighted average exercise price, Options assumed in Merger
Exercised		(12,000	)		1.94
Forfeited		(31,731	)		1.66
Expired		(38,687	)		1.24
Balance as of June 30, 2020		876,681		$	1.65		8.4

Balance as of January 1, 2021		756,383			1.82		8.7
Granted		1,229,590			4.61
Additional options to StemoniX option holders		205,856			4.61
Options assumed in Merger		55,840			45.95
Exercised		(29,916	)		1.24
Forfeited		(34,717	)		2.00
Expired		(7,000	)		1.39
Balance as of June 30, 2021		2,176,036		$	4.80		9.0
Exercisable as of June 30, 2021		594,199		$	5.84		7.7

The Company recognized stock-based compensation related to different instruments for the three and six months ended June 30 as follows:

	2021		2020		2021		2020
	For the three months ended June 30,				For the six months ended June 30,
	2021		2020		2021		2020
Stock Options	$	352	$	55	$	718	$	97
Shares issued for services		10		6		10		36
Total	$	362	$	61	$	728	$	133